Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 29, 2009 Brian Orelli	Merck's Bad News Nothing to Sneeze At The U.S. Patent and Trademark Office reexamination of Merck's patent on allergy medication, Singulair, is nothing to sneeze at. The $2.8 billion worth of Singulair that Merck sold in the U.S. last year made up 12% of its total pharmaceutical sales.
The Motley Fool October 22, 2008 Brian Orelli	Merck's a Bloated Garbage Heap of Stale Drugs Now Merck is planning on cutting 12% of its workforce in the hopes of saving $4 billion through 2013.
The Motley Fool July 8, 2010 Brian Orelli	Surprise Us in a Good Way, Merck Keeping up productivity during plant closures won't be easy.
Chemistry World February 18, 2010 Matt Wilkinson	Merck joins the cost-cutting crowd Following its merger with Schering-Plough, US drug giant Merck & Co. has announced a 'merger restructuring plan' that in its first phase will see 17,500 jobs cut.
The Motley Fool May 5, 2010 Brian Orelli	Doubled Revenue, but Not High Growth An acquisition and some rearrangements make Merck's revenue line sound better than it is.
Chemistry World October 23, 2008 Matt Wilkinson	Merck to slash more jobs Beleaguered US pharma giant, Merck & Co., has announced new restructuring plans that will see the company cut 7,200 jobs in an effort to save up to $4.2 billion
The Motley Fool May 6, 2008 Brian Orelli	A Sign of the Pharma Times Merck is the latest big pharma cutting jobs to improve its bottom line.
The Motley Fool July 30, 2010 Brian Orelli	It's Hard to Get Excited About 92% Revenue Growth Especially when revenue dropped on a comparable basis.
The Motley Fool December 5, 2007 Brian Orelli	Merck Stays Conservative Merck sets the bar low with its 2008 guidance. Is the company being overly cautious?
The Motley Fool January 10, 2012 Sean Williams	2012 Preview: Merck The biggest question mark facing the pharmaceutical behemoth in 2012 is just how badly it will be affected by losing patent-exclusivity rights on its biggest drug, Singulair.
The Motley Fool July 21, 2009 Brian Orelli	Merck and Schering: A Less Ugly Bride and Groom Merck and Schering-Plough are up today on "better than expected" earnings, but the bride and groom don't look all that great heading into the wedding.
The Motley Fool April 30, 2011 Brian Orelli	No Long-Term Guidance? No Problem! Looking good, Merck.
The Motley Fool October 23, 2007 Brian Orelli	Old Merck on New Drugs It looks like the old Merck is back, with new drugs driving double-digit sales growth in the third-quarter.
Chemistry World October 4, 2013 Andy Extance	Amid huge cuts, Merck vows research focus US-based drug giant Merck & Co will cut 8,500 more jobs as it seeks to cut costs by $2.5 billion
The Motley Fool October 23, 2006 Brian Lawler	Merck Mints Money The pharmaceutical hangs on, despite ongoing Vioxx woes. Conservative investors may do best to stay away from Merck until a lower share-price opportunity presents itself, now that shares are no longer sporting such a large Vioxx discount.
Chemistry World March 13, 2009 Sarah Houlton	Mega mergers sweep pharma industry Just six weeks after Pfizer agreed to buy Wyeth, US pharma companies Merck & Co. and Schering-Plough announced they are to merge.
The Motley Fool December 21, 2006 Brian Lawler	Dueling Fools: Merck Bull Rebuttal Plenty of cash. Big pipeline. Not to worry. The future can't be predicted, but Merck's history shows its ability to weather even the toughest pharmaceutical-development environments.
The Motley Fool July 29, 2011 Brian Orelli	Merck's Making All the Right Long-Term Moves Job cuts, but they're not in research.
Chemistry World June 20, 2012	Nasonex patent ruling goes against Merck & Co The US court ruled that, although the Merck patent in question was valid, it should not stop Canadian generics company Apotex marketing its mometasone furoate product.
The Motley Fool February 16, 2010 Brian Orelli	Merck Gets a Pass, for Now Its first quarter looks promising, but not as good as could be hoped.
The Motley Fool January 31, 2008 Brian Orelli	One Last Look at Pre-Enhance Merck Investors show they care more about Merck's future than its Q4 results.
The Motley Fool May 21, 2009 Brian Orelli	Not So Fast, Schering ... er, Merck ... er, Whoever You Are Merck got cute with its acquisition of Schering-Plough by setting up the merger so that Schering is technically merging with Merck and then changing its name to Merck. That seemingly schizophrenic move had a purpose.
Pharmaceutical Executive January 1, 2006 Jeannette Park	Thought Leader: Q&A with Cheryl Buxton Cheryl Buxton talks about what impact Merck's decision to cut nearly 11 percent of its work force - in hopes of saving $4 billion dollars by 2010 - will have on the company's future.
The Motley Fool October 24, 2005 Stephen D. Simpson	Merck Needs to Take Its Medicine It will be a long, long time before business at the pharmaceutical returns to business as usual. Turnarounds can pay off for patient investors.
The Motley Fool August 28, 2007 Brian Orelli	A Combination to Clear Your Head Merck and Schering-Plough get together again. But who can blame them? Their partnerships have been making both companies lots of money. Investors, take note.
The Motley Fool January 25, 2005 Stephen D. Simpson	Prognosis Good for Merck The pharmaceutical weathered a tough year but should ride out its Vioxx troubles. While strict value investors may be put off, risk-tolerant investors can buy these shares today.
The Motley Fool January 19, 2012 Sean Williams	No Vacancy: Workers Need Not Apply to This Sector Pharmaceutical and biotech layoffs are kicking into high gear.
The Motley Fool September 1, 2009 Brian Orelli	Merck to Bride: Leave the Jewelry at Home The new Merck will look a lot like the old Merck at the top, even though about 40% of Schering's senior leaders will be headed to the new company.
The Motley Fool April 15, 2011 Brian Orelli	Dark Clouds Lift Over Pharma Dispute The case of who bought whom in the Merck -Schering-Plough deal has ended in a draw.
The Motley Fool February 3, 2011 Brian Orelli	Get Ready for Merck's Bumpy Ride Long-term earnings guidance gets thrown out the window.
BusinessWeek December 22, 2003 Robert Barker	A Stimulant For Depressed Drug Stocks? For a bunch of can't-miss stocks, the big drugmakers sure did miss out on 2003's bull run. The dozen drug companies in the Standard & Poor's 500-stock index have returned 10% this year, vs. the index' 22%. But the market is now failing to credit the companies' strengths.
The Motley Fool January 31, 2006 Stephen D. Simpson	Merck Marking Time There won't be much good news for this pharmaceutical's investors until new products hit the market. If you already own Merck, you probably understand that patience will be the order of the day here.
The Motley Fool April 28, 2009 Brian Orelli	The Costs of Being Pfizer With Pfizer having announced its intention to buy Wyeth this quarter, investors may have worried that the negotiating and pre-acquisition planning caused management to be distracted, but that doesn't seem to be the case.
The Motley Fool March 2, 2010 Brian Orelli	Merck: Poised for Growth and Eager to Go Merck needs its new, stronger, post-acquisition pipeline to pay off.
The Motley Fool July 18, 2008 Brian Orelli	Foolish Forecast: How Quickly Can Merck Turn It Around? Views you can use to get clues on the news.
Chemistry World April 2, 2007	European Generics Suppliers Hit Generics drug manufacturers have lost a slice of their market with the reinstatement of a European patent covering Merck's multi-billion-dollar osteoporosis drug, Fosamax.
The Motley Fool October 21, 2004 Brian Gorman	Merck Is Down But Not Out The pharma's woes may have silver linings. For now, the company's investors might want to sit tight.
The Motley Fool December 21, 2006 Brian Lawler	Dueling Fools: Merck Bull What you are getting with Merck is one of the best-managed pharmas out there that will be experiencing solid double-digit earnings growth in the not-too-distant future with a smart dividend payout.
The Motley Fool March 18, 2009 Brian Orelli	Merck Pummels Pfizer One of these acquisitions is not like the other.
The Motley Fool January 26, 2006 Rich Duprey	Will Acquisitions Patch Merck's Pipeline? The pharmaceutical giant announces a biotech shopping spree. A few key acquisitions that contribute late-stage drugs and significant revenue might be all Merck needs to keep its pipeline open. Investors, take note.
The Motley Fool March 9, 2009 Brian Orelli	Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth.
The Motley Fool January 31, 2007 Brian Lawler	Merck Plays the Waiting Game New acquisitions may help the drugmaker weather tough times. Investors, take note.
The Motley Fool December 10, 2008 Brian Orelli	Merck: Same Plan, With a Twist With increasing generic competition and languishing sales of cholesterol-lowering drugs Vytorin and Zetia, Merck is doing its best to replace sales by pushing new drugs through its pipeline.
The Motley Fool March 2, 2005 Brant David McLaughlin	Merck's Road to Recovery Merck didn't get to where it is by being shortsighted, and management has no plans to start now. Investors would be wise not to take on an excessively negative attitude toward the company in the wake of some dark news.
The Motley Fool August 22, 2008 Brian Orelli	Abbott Tries a Crash Diet The health-care conglomerate is cutting jobs in its diagnostic testing division.
The Motley Fool September 12, 2005 M.D. Mitchell	Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch.
The Motley Fool November 13, 2007 Brian Orelli	Merck: Case Closed? Now that Merck has settled its lawsuit, it can get back to business, focusing on continued growth from its cholesterol drugs, new diabetic medication, and cervical cancer vaccine. Investors, take note.
The Motley Fool November 25, 2011 Dan Caplinger	Has Merck Become the Perfect Stock? Like most other pharma companies, Merck is dealing with the imminent loss of patent protection on one of its blockbuster drugs.
Chemistry World April 20, 2009 Phil Taylor	GSK and Pfizer join forces in fight against HIV The world's two biggest pharmaceutical companies, GlaxoSmithKline (GSK) and Pfizer, are bundling their HIV activities into a joint venture company in a move they claim is both 'unique and innovative'.
BusinessWeek January 12, 2004	Pharmaceuticals: For Drugmakers, There's No Panacea Blockbusters are in store, but the cost of R&D, ads, and factory fixes will eat profits. Pressure from insurers and government on prices will be a drag on revenues.